BeiGene | Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Beigene Study ID

BGB-3111-206

ClinicalTrials.gov ID

NCT03206970

China Drug Trials ID

CTR20160888

Sex: All

Age: 18 Years / 75 Years

Study Protocol Statistical Analysis Plan

Sex: All

Age: 18 Years / 75 Years

Study Protocol Statistical Analysis Plan